US Patent Issued to JAZZ PHARMACEUTICALS RESEARCH UK on July 15 for "Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy" (British Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,357,586, issued on July 15, was assigned to JAZZ PHARMACEUTICALS RESEARCH UK Ltd. (Sittingbourne, Great Britain).

"Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy" was invented by Benjamin Whalley (Reading, Great Britain), Claire Williams (Reading, Great Britain) and Gary Stephens (Reading, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of e...